New anthrarobin acyl derivatives as butyrylcholinesterase inhibitors: synthesis, and studies.

To treat Alzheimer's disease (AD), the available candidates are effective only against mild AD or have side effects. So, a study was planned to synthesis new candidates that may have good potential to treat AD. A series of new anthrarobin acyl derivatives (-) were synthesized by the reaction of anthrarobin () and acetic anhydride/acyl chlorides. The product were characterized by H NMR and EI-MS, and evaluated for butyrylcholinesterase (BuChE) inhibition activity. Compounds and showed notable BuChE inhibitory potential with IC 5.3 ± 1.23 and 17.2 ± 0.47 μM, respectively when compared with the standard eserine (IC 7.8 ± 0.27 μM), compound showed potent BuChE inhibition potential than the standard eserine. The active compounds and have acyl groups at 2-OH and 10-OH positions which may be responsible for inhibitory potential as this orientation is absent in other products. studies of and products revealed the high inhibitory potential due to stable binding of ligand with the BuChE active sites with docking energy score -18.8779 kcal/mol and -23.1159 kcal/mol, respectively. Subsequently, compound that have potent BuChE inhibitory activity could be the potential candidate for drug development for Alzheimer's disease.